Orion - Articles of association

Amendment of Section 12 of Articles of Association entered in the Trade Register

Orion Corporation - Stock Exchange Release


ORION CORPORATION: Amendment of Section 12 of Articles of Association entered in
the Trade Register


ORION CORPORATION   STOCK EXCHANGE RELEASE  8 April 2010  AT 9.50 AM
EET


Amendment of Section 12 of Articles of Association entered in the Trade Register


The amendment of Section 12 of the Articles of Association of Orion Corporation
in accordance with the decision by the AGM held on 24 March 2010 has been
entered in the Trade Register. The current Articles of Association are available
on the company's website in the address www.orion.fi/articles-of-association<http://www.orion.fi/articles-of-association>. The decisions of the AGM were
published in a Stock Exchange Release of 24 March 2010.


Orion Corporation


Timo Lappalainen          Olli Huotari
President and CEO       SVP, Corporate Functions


Contact person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, GSM +358
50 966 3054



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi <http://www.orion.fi/>



Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler(®)
pulmonary drugs.

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.


[HUG#1401325]